Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 175 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Volunteers (Part 1) Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

NCT04368988
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Normal saline solution (NSS), Placebo - Phase 1, Normal saline solution (NSS), Placebo - Phase 2, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Normal saline solution (NSS), Placebo, Day 21 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 84 Years
Enrollment
1,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

NCT04839393
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women

NCT07542847
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OPC-167832, Itraconazole, Carbamazepine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants

NCT05205447
View directory record Official record
Conditions
Healthy
Interventions
LY3410738, Itraconazole, Carbamazepine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 29, 2026, 1:35 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

NCT07766369
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

NCT06793943
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zasocitinib, COC, Metformin, Digoxin, Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

NCT06363630
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Itraconazole, Rifampin, Golcadomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Atlanta, Georgia • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

NCT05901714
View directory record Official record
Conditions
Healthy Participants
Interventions
Afimetoran, Phenytoin, Midazolam
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults

NCT04580654
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CSL312
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

NCT01733875
View directory record Official record
Conditions
Healthy
Interventions
CC-220 0.03 mg, CC-220 0.1 mg, CC-220 0.3 mg, CC-220 1 mg, CC-220 2 mg, Placebo, CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)

NCT01951560
View directory record Official record
Conditions
Shock,Hemorrhagic
Interventions
Valproic Acid, Isotonic saline solution
Drug
Lead sponsor
Dr. Hasan Alam
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Sep 29, 2026, 1:35 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
GSK4527363, Placebo matching GSK4527363, Belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • Aurora, Colorado • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

NCT07119125
View directory record Official record
Conditions
Healthy Volunteers, Elevated CRP
Interventions
MRT-8102, Placebo
Drug
Lead sponsor
Monte Rosa Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Lenexa, Kansas • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects

NCT05997641
View directory record Official record
Conditions
Healthy, Safety and Tolerability
Interventions
DF-003, Placebo
Drug
Lead sponsor
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants

NCT05051553
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Fedratinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

NCT05877053
View directory record Official record
Conditions
Healthy Participants
Interventions
CK-4021586, Placebo for CK-4021586
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants

NCT05134337
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LOXO-305, Itraconazole, Rifampin
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 29, 2026, 1:35 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

NCT05761301
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
ALN-KHK, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Vista, California • Lake Worth, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

NCT06729970
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Xanomeline/Trospium Chloride, Lithium, Valproic Acid, Lamotrigine
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

NCT07314346
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Hollywood, Florida • Overland Park, Kansas • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

NCT07780383
View directory record Official record
Conditions
Alzheimer's Disease, Healthy Participants
Interventions
BMS-986446
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
6
States / cities
Anaheim, California • Bradenton, Florida • Daytona Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT07205081
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions
ATTO-3712, Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
9
States / cities
Encinitas, California • Fountain Valley, California • Huntington Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

NCT05831111
View directory record Official record
Conditions
Epstein-Barr Virus Infection
Interventions
mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
482 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
34
States / cities
Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

NCT01511432
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C, telaprevir Formulation D
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Sep 29, 2026, 1:35 PM EDT